home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550861.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
3KB
|
47 lines
Document 0861
DOCN M9550861
TI [Immune response to antibiotics in patients with secondary
immunodeficiencies]
DT 9505
AU Meroni PL; Istituto di Medicina Interna, Malattie Infettive &;
Immunopatologia, Universita degli Studi, Milano.
SO J Chemother. 1994 Aug;6 Suppl 3:16-8. Unique Identifier : AIDSLINE
MED/95165192
AB A biological response modifier (BRM) has been defined as an agent able
to modulate effector mechanisms or mediators of host defence. Some
antibiotic molecules have been shown to display a BRM like activity,
being able to enhance immune responses (certain cephalosporins), to
synergize with the immune effectors (macrolides, quinolones) or
alternatively, to depress immune functions (tetracyclines or antimycotic
drugs). The BRM-like activity of different antibiotic molecules has been
widely reported in in vitro studies as well as ex vivo in experimental
animal models. Only recently some Authors have approached the problem by
investigating whether the in vivo administration of antibiotic was able
to affect different immune effector functions, either in healthy
subjects or in patients. The main question in the field is the possible
clinical impact of the connections between antibiotics and the immune
system, particularly in subjects with acquired immunodeficiency in whom
the impairment of the immune responses leads to increased susceptibility
to infectious processes. Ex vivo data seem to suggest that cefodizime,
one of the newest third-generation cephalosporins, is able to enhance
phagocyte and mononuclear cell functions in healthy volunteers, thus
confirming the possibility of combining an antibacterial efficacy with
the ability to restore or enhance immune responses. Comparable data in
studies investigating the effect of cefodizime on immune functions in
immunocompromised patients such as elderly subjects, hemodialyzed or
diabetic patients, BPCO subjects, patients undergoing surgical stress
and patients with multiple myeloma are more important from a practical
clinical point of view.(ABSTRACT TRUNCATED AT 250 WORDS)
DE Aged Antibiotics/*PHARMACOLOGY/THERAPEUTIC USE Bacterial
Infections/DRUG THERAPY/IMMUNOLOGY *Biological Response Modifiers
Comparative Study English Abstract Human Immunity/*DRUG EFFECTS
Immunity, Natural/DRUG EFFECTS Immunocompromised Host/DRUG EFFECTS
Immunologic Deficiency Syndromes/*DRUG THERAPY/IMMUNOLOGY In Vitro
Mycoses/DRUG THERAPY/IMMUNOLOGY Phagocytes/DRUG EFFECTS Protozoan
Infections/DRUG THERAPY/IMMUNOLOGY Virus Diseases/DRUG
THERAPY/IMMUNOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).